SEC Form 4 · accession 0001177648-18-000044
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nathalie Adda
Officer — Sr. VP & Chief Medical Officer
Period of report
Nov 16, 2018
Accepted (ET)
Nov 20, 2018 · 8:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $81.20 | Nov 16, 2018 | A | 20,000 | A | — | Nov 16, 2028 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 16, 2018).